{
    "clinical_study": {
        "@rank": "151225", 
        "arm_group": [
            {
                "arm_group_label": "Ferinject\u00ae Group", 
                "arm_group_type": "Experimental", 
                "description": "Ferinject\u00aeto be administered as IV drip infusion or undiluted bolus injection  to consented patients with 7g/dl\u2264Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer."
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection  to consented patients with 7g/dl\u2264Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the efficacy of Ferinject\u00ae in improving acute isovolemic\n      anemia after gastrectomy for gastric cancer in terms of Quality of life(QOL )and objective\n      measures (Hb and iron parameters).\n\n      Furthermore, the tolerability and safety of Ferinject\u00ae treatment will be evaluated."
        }, 
        "brief_title": "Ferinject\u00ae Assessment In GastRectomy Patients With Acute Isovolemic Anemia (FAIRY)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Anemia", 
        "condition_browse": {
            "mesh_term": "Anemia"
        }, 
        "detailed_description": {
            "textblock": "Randomized patient-blind placebo controlled study. Hb level of 10 g/dl will be used as a\n      cut-off value for our study based on the guidelines published by American Society of\n      Clinical Oncology and the American Society of Hematology for the treatment of cancer-related\n      anemia,  recommending Hb<10 g/dl as a treatment threshold.\n\n      Ferinject\u00ae to be administered based on Hb and body weight per approved summary of product\n      characteristics (SmPC).\n\n      5 - 7 days after gastrectomy for gastric cancer, consented patients with 7g/dl\u2264Hb<10g/dl\n      will be administered Ferinject\u00ae or placebo (normal saline) based on the results of\n      randomization.\n\n      \u2022 Study Group Ferinject\u00aeto be administered as IV drip infusion or undiluted bolus injection\n      with a minimum administration time of 15minutes (for 1000mg single administration) for body\n      weight \u226550 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .\n\n      Note, Ferinject\u00ae should be administered to a maximum of 20mg iron/kg. Therefore in patients\n      with a body weight <50kg, administration of Ferinject\u00ae should be limited to 500mg  at\n      baseline . All patients with a serum ferritin value <15ng/mL at week 4 visit that a second\n      dose (of 500mg iron or equivalent placebo) will be  given.(Study group: Ferinject\u00ae500mg,\n      Control Group:Placebo)\n\n      \u2022 Control Group Placebo will be in the form of normal saline administered over same time\n      period as equivalent Ferinject\u00ae administration. IV drip infusion or undiluted bolus\n      injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as\n      bolus injection) for body weight \u226550 Kg or 6 minutes (100mL normal as infusion or 10mL as\n      bolus injection) for body weight <50 Kg."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2265 19 years old\n\n          -  7g/dl \u2264 Hb < 10g/dl at 5 - 7 days after gastrectomy for gastric cancer\n\n          -  signed written informed consent\n\n        Exclusion Criteria:\n\n          -  a concurrent medical condition(s) that would prevent compliance or participation or\n             jeopardize the health of the patient\n\n          -  hypersensitivity to any component of the formulation\n\n          -  active severe infection/inflammation\n\n          -  History of transfusion, erythropoietin, > 500 mg intravenous iron administration\n             within 4 weeks prior to screening.\n\n          -  History of acquired iron overload.\n\n          -  Pregnancy or lactation.\n\n          -  Decreased renal function (defined as creatinine clearance < 50 mL/min calculated by\n             Cockcroft-Gault)\n\n          -  Chronic liver disease or increase of liver enzymes (ALT, AST) > 3 times the upper\n             limit of normal range.\n\n          -  Participation in any other interventional study within 1 month prior to screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725789", 
            "org_study_id": "NCCCTS-12-644"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ferinject\u00ae Group", 
                "description": "Ferinject\u00aeto be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight \u226550 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .\nNote, Ferinject\u00ae should be administered to a maximum of 20mg iron/kg. Therefore in patients with a body weight <50kg, administration of Ferinject\u00ae should be limited to 500mg  at baseline . All patients with a serum ferritin value <15ng/mL and Hb<10g/dl at week 3 visit that a second dose (of 500mg iron or equivalent placebo) will be  given.(Study group: Ferinject\u00ae500mg, Control Group:Placebo)", 
                "intervention_name": "Ferinject\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "Ferric carboxymaltose"
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "description": "Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject\u00ae administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight \u226550 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.", 
                "intervention_name": "normal saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ferric Compounds"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Acute isovolemic anemia after gastrectomy for gastic cancer", 
        "lastchanged_date": "February 25, 2014", 
        "location": [
            {
                "contact": {
                    "email": "parkyk@jnu.ac.kr", 
                    "last_name": "Young Kyu Park, Dr", 
                    "phone": "+82+10-7173-1196"
                }, 
                "facility": {
                    "address": {
                        "city": "Hwasun", 
                        "country": "Korea, Republic of", 
                        "state": "Chollanam Do", 
                        "zip": "519-763"
                    }, 
                    "name": "Chonnam National University Hwasun Hospital"
                }, 
                "investigator": {
                    "last_name": "Young Kyu Park, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gskim@ncc.re.kr", 
                    "last_name": "Young-Woo Kim, MD, PHD", 
                    "phone": "+82-31-920-1635"
                }, 
                "facility": {
                    "address": {
                        "city": "Goyang", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "411-764"
                    }, 
                    "name": "National Cancer Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Keun Won Ryu, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Byoung -Ho Nam, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Young-Woo Kim, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Hong Man Yoon, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "MiJeong Kim, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Bangwool Um, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "wyu@knu.ac.kr", 
                    "last_name": "Wansik Yu, Dr", 
                    "phone": "+82+10-4225-5616"
                }, 
                "facility": {
                    "address": {
                        "city": "Dae Gu", 
                        "country": "Korea, Republic of", 
                        "zip": "700-721"
                    }, 
                    "name": "Kyungpook national university hospital"
                }, 
                "investigator": {
                    "last_name": "Wansik Yu, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jeong-Whan YUK, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jae-Moon Bae, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sung-Hoon ROH"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Yonsei University"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Patient -Blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject\u00ae) With Placebo in Patients With Acute Isovolemic Anemia After Gastrectomy", 
        "overall_contact": {
            "email": "gskim@ncc.re.kr", 
            "last_name": "Young  Woo Kim, MD, PhD", 
            "phone": "82-31-920-1635"
        }, 
        "overall_contact_backup": {
            "email": "trueclear@ncc.re.kr", 
            "last_name": "Youngsook Kim, BS", 
            "phone": "82-31-920-2895"
        }, 
        "overall_official": {
            "affiliation": "National Cancer Center, Rep. of Korea", 
            "last_name": "Young Woo Kim, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "\u2022\tNumber of responders (Hb increase \u22652 g/dL with respect to the baseline Hb value and/or Hb \u226511g/dL ) by 12 weeks (independent of alternative anaemia management including transfusion or ESA use). Note, if patient requires an ESA or blood transfusion by week 12 will be considered a non-responder.", 
            "measure": "\u2022 Number of responders", 
            "safety_issue": "No", 
            "time_frame": "12 weeks post baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725789"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Cancer Center, Korea", 
            "investigator_full_name": "Young-Woo Kim", 
            "investigator_title": "Head of Department of Gastric Cancer Research", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022\tPercentage of patients with Hb \u226510, 11 and 12 g/dL at 4 and 12 weeks (independent of alternative anaemia management including transfusion or ESA use)", 
                "measure": "\u2022 Percentage of patients with Hb \u226510, 11 and 12 g/dL", 
                "safety_issue": "No", 
                "time_frame": "3weeks , 12 weeks post baseline"
            }, 
            {
                "description": "\u2022\tPercentage of patients requiring alternative anaemia management therapy", 
                "measure": "\u2022 Percentage of patients requiring alternative anaemia management therapy", 
                "safety_issue": "No", 
                "time_frame": "12 weeks post baseline"
            }, 
            {
                "description": "\u2022\tAverage time to response(from Ferinjec\u00ae administration  to  Assessment) (Hb increase \u22652 g/dL with respect to the baseline Hb value and/or Hb \u226510 g/dL) independent of alternative anaemia management including transfusion or ESA use", 
                "measure": "\u2022 Average time to response", 
                "safety_issue": "No", 
                "time_frame": "12  weeks post baseline"
            }, 
            {
                "description": "\u2022\tSelf-reported patient assessment of EORTC QLQ C-30 and Sto-22 at 3 weeks and 12 weeks", 
                "measure": "\u2022 Self-reported patient assessment of EORTC QLQ C-30 and Sto-22", 
                "safety_issue": "No", 
                "time_frame": "3weeks, 12weeks post baseline"
            }, 
            {
                "description": "\u2022\tEvolution of Hb, ferritin and TSAT over the study duration (12weeks) independent of alternative anaemia management including transfusion or ESA use", 
                "measure": "\u2022 Evolution of Hb, ferritin and TSAT", 
                "safety_issue": "No", 
                "time_frame": "12 weeks post baseline"
            }, 
            {
                "description": "\u2022\tadverse events: type, nature, incidence and outcome", 
                "measure": "\u2022 adverse events: type, nature, incidence and outcome", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 weeks post baseline"
            }
        ], 
        "source": "National Cancer Center, Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Center, Korea", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}